跳转至内容
Merck
CN

890850C

Avanti

18:1 DAP

Avanti Research - A Croda Brand 890850C

别名:

1,2-二油酰-3-二甲基铵-丙烷(DODAP)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C41H77NO4
分子量:
648.05
UNSPSC代码:
12352211
NACRES:
NA.25

形式

liquid

包装

pkg of 1 × 2.5 mL (890850C-25mg)
pkg of 2 × 4 mL (890850C-200mg)

制造商/商品名称

Avanti Research - A Croda Brand 890850C

浓度

10 mg/mL (890850C-25mg)
25 mg/mL (890850C-200mg)

脂质类型

transfection
cationic lipids

运输

dry ice

储存温度

−20°C

SMILES字符串

[H]C(CN(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O

InChI

1S/C41H77NO4/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-40(43)45-38-39(37-42(3)4)46-41(44)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,39H,5-18,23-38H2,1-4H3/b21-19-,22-20-

InChI key

NYDLOCKCVISJKK-WRBBJXAJSA-N

一般描述

18:1 DAP是一种阳离子脂质。作为pH敏感性转染试剂,可用于制备阳离子脂质体。

应用

18:1 DAP适用于:
  • 作为脂质双分子层组分
  • 制备稳定的核酸脂质囊泡
  • 含反义寡脱氧核糖核苷酸(ODN)的叶酸(FA)靶向脂质体和非靶向脂质体的制备和理化特性表征

包装

5 mL透明玻璃密封安瓿(890850C-200mg)
5 mL透明玻璃密封安瓿(890850C-25mg)

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

靶器官

Liver,Kidney, Respiratory system

储存分类代码

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

闪点(°F)

does not flash

闪点(°C)

does not flash

法规信息

易制毒化学品(2类)
危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study
Saffari M, et al.
Iranian Journal of Pharmaceutical Research : IJPR, 12, 3-3 (2013)
Transferrin-conjugated SNALPs encapsulating 2?-O-methylated miR-34a for the treatment of multiple myeloma
Scognamiglio I, et al.
BioMed Research International, 2014 (2014)
Nonequilibrium adhesion patterns at lipid bilayer junctions
Parthasarathy R, et al.
The Journal of Physical Chemistry B, 108(2), 649-657 (2004)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门